Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia

Leukemia. 2019 Jul;33(7):1805-1810. doi: 10.1038/s41375-018-0343-2. Epub 2019 Jan 24.

Christopher F Krombholz¹, Lorena Gallego-Villar¹, Sushree S Sahoo¹, Pritam K Panda¹, Marcin W Wlodarski^{1

2}, Konrad Aumann³, Mark Hartmann⁴, Daniel B Lipka⁴, Michael Daskalakis⁴, Christoph Plass^{2

4}, Charlotte M Niemeyer^{1

2}, Miriam Erlacher^{1

2}, Christian Flotho^{5

6}

¹ Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
² German Cancer Consortium, Heidelberg, Germany.
³ Department of Pathology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁴ Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center, Heidelberg, Germany.
⁵ Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. [email protected].
⁶ German Cancer Consortium, Heidelberg, Germany. [email protected].

No abstract available

Publication types